Insider option exercise and index additions put Veracyte in focus

Veracyte (VCYT) is back on investors’ radar after Vice President and Chief Accounting Officer Jonathan Wygant exercised 24,000 stock options and immediately sold the resulting shares for about US$1.09 million.

The transaction, which reduced his direct stake by 34.57% to 45,434 shares, comes shortly after Veracyte was added to several Russell indices, including small cap value and growth defensive benchmarks.

At a share price of US$56.16, Veracyte has pulled back in the last week, with a 7 day share price return that declined 4.38%, but the 90 day share price return of 71.90% and 1 year total shareholder return of 111.29% point to strong recent momentum.

If Veracyte’s recent move and index additions have caught your attention, this can be a good moment to see what else is gaining attention in healthcare, including 40 healthcare AI stocks

Veracyte looks like a solid diagnostics business, and the recent surge in the share price plus fresh index inclusion underline that perception. The next step is clear: is the stock’s current valuation still reasonable?

Most Popular Narrative: 14.4% Overvalued

Veracyte’s most followed narrative pegs fair value at $49.10, which sits below the recent $56.16 close, so investors are weighing how much optimism is already in the price.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Read the complete narrative. Read the complete narrative.

Want to see what justifies that valuation gap between price and fair value? The narrative leans heavily on revenue compounding, margin support and a punchy earnings multiple. The exact mix of those inputs may surprise you.

Result: Fair Value of $49.10 (OVERVALUED)

However, Veracyte’s heavy reliance on Afirma and Decipher, as well as the need to secure and maintain payer coverage for newer tests, could quickly challenge this overvaluation narrative.

Another View: Veracyte Through a Cash Flow Lens

The analyst narrative flags Veracyte as about 14.4% overvalued at a fair value of $49.10, yet our DCF model points to a higher fair value of $59.69, with the stock trading at $56.16. One framework says caution; the other leaves some headroom. Which set of assumptions do you find more convincing?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Veracyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution around Veracyte has you thinking, take a closer look at the data and decide quickly where you stand, starting with the 3 key rewards.

Looking for more investment ideas beyond Veracyte?

Veracyte might be front of mind today, but real progress often comes from lining up a short list of strong alternatives and acting before the crowd catches on.

• Spot potential value opportunities early by scanning 45 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their qualities.
• Prioritise stability and peace of mind by reviewing 74 resilient stocks with low risk scores that carry lower risk scores while still offering meaningful exposure to the market.
• Get ahead of the crowd by uncovering screener containing 18 high quality undiscovered gems that investors are not widely talking about yet but already show solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.